Last updated on July 2017

FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate


Brief description of study

FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Detailed Study Description

FINCH 1 is enrolling RA patients who have taken methotrexate (also known as MTX, TREXALL, or RASUVO) but have not yet tried a biologic treatment. Filgotinib (study drug) is an oral medication designed to reduce joint inflammation.

Clinical Study Identifier: TX151159

Find a site near you

Start Over

The Osteoporosis & Clinical Trials Center

Klein & Associates, M.D., P.A<br /> 346 Mill Street Hagerstown, MD USA
  Connect »